Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gianina Cristiu

Registered Nurse, Psychiatric/Mental Health, Adult Detroit, MI Nurse Practitioner

NPI 1720232689 CMS profile 11157679

10 Peterboro St, Detroit, MI 48201

Open in the dashboard

General payments

$3,044

127 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gianina Cristiu of Detroit, MI is reported in the CMS Open Payments database as having received $3,044 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Registered Nurse, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,195 42
2024 General $931 40
2023 General $700 34
2022 General $200 10
2021 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gianina Cristiu
  • Registered Nurse, Psychiatric/Mental Health, Adult median
  • Middle half of Registered Nurse, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Gianina Cristiu were reported at $1,195. Among 96 Registered Nurse, Psychiatric/Mental Health, Adult profiles paid that year, the median was $121 and the middle half received between $39 and $265.

Show as a table
Year Gianina Cristiu Registered Nurse, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $18 $108 $31–$328 $132
2022 $200 $99 $22–$306 $149
2023 $700 $99 $43–$313 $160
2024 $931 $119 $30–$319 $164
2025 $1,195 $121 $39–$265 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Indivior Inc. $598 25 payments
  2. Otsuka America Pharmaceutical, Inc. $500 26 payments
  3. Teva Pharmaceuticals USA, Inc. $395 12 payments
  4. Alkermes, Inc. $394 13 payments
  5. E.R. Squibb & Sons, L.L.C. $330 11 payments
  6. Neurocrine Biosciences, Inc. $293 12 payments
  7. ITI, Inc. $140 8 payments
  8. AbbVie, Inc. $110 6 payments
  9. Vanda Pharmaceuticals Inc. $108 5 payments
  10. Lundbeck LLC $74 4 payments
  11. Other $103 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,932 126 payments
  2. Education $111 1 payment
Products named General payments · program years 2021–2025
  1. PERSERIS $598 25 payments
  2. LYBALVI $394 13 payments
  3. COBENFY $330 11 payments
  4. INGREZZA $293 12 payments
  5. REXULTI $281 13 payments
  6. ARISTADA Cns $249 11 payments
  7. ARISTADA Cns $249 11 payments
  8. UZEDY $248 9 payments
  9. ARISTADA Cns $209 9 payments
  10. ARISTADA Cns $209 9 payments
  11. Other $1,509 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

5,156

Median for Nurse Practitioner: 389

Drug cost

$783,409

Median for Nurse Practitioner: $21,885

Branded share of claims

18.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 80 $239,607
Invega Trinza Paliperidone Palmitate Brand 26 $178,737
Rexulti Brexpiprazole Brand 68 $97,063
Ingrezza Valbenazine Tosylate Brand 13 $97,024
Vraylar Cariprazine Hcl Brand 29 $41,405
Lurasidone Hcl Generic 104 $16,979
Trintellix Vortioxetine Hydrobromide Brand 32 $14,851
Clozapine Generic 159 $11,877
Aripiprazole Generic 263 $9,280
Clozapine Odt Clozapine Brand 11 $4,630

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$19,556

Medicare's payments for the services billed

Medicare patients

64

Average age 56

Services billed

272

37 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Depression 41%
Diabetes 28%
Arthritis 27%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PERSERIS
  • Indivior Inc. $226
$226 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $185
$185 13 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $171
$171 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $56
  • Lundbeck LLC $50
$105 68 —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Psychiatric/Mental Health, Adult in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record